A Phase 3 consideration involving ...
A Phase 3 consideration involving 50 randomized subjects evaluated the use of satraplatin (GPC Biotech AG, Martinsried/ Munich, Germany) plus prednisone compared to prednisone alone for use as a first-fine chemotherapy treatment in hormone-refractory prostate cancer. The contemplation results showed that the combined put drugs into treatment significantly lengthened the time to disease progression. The median time to disease progression was 52 month for the combination and 25 month for
|